Adam Bowman, MD
Ophthalmology · Salt Lake City, UTNPI 1184846131
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Amgen at 37.7% of the total. Reporting peaked in 2022 at $1,914 and has fallen 98.9% since, to $20 in 2025.
Across 36 payments — averaging $128.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$204
- Alcon$179
- Genentech USA, Inc.$151
- Regeneron Healthcare Solutions, Inc.$146
- plus $680 from 9 others
What the payments were for
- Speaking & faculty fees$1,74038%
- Travel & lodging$1,15025%
- Food & beverage$1,70737%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $1,740 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $1,517 |
| AbbVie(2 entities) | 5 | $204 |
| Alcon | 2 | $179 |
| Genentech USA, Inc. | 2 | $151 |
| Regeneron Healthcare Solutions, Inc. | 2 | $146 |
| Apellis Pharmaceuticals, Inc. | 2 | $142 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $125 |
| Astellas Pharma US Inc | 1 | $124 |
| Sun Pharmaceutical Industries Inc. | 6 | $98 |
| Carl Zeiss Meditec USA, Inc. | 1 | $82 |
| Novartis | 4 | $57 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,740
- Tecnis 1-piece IOL$1,443
- Tecnis 3-piece IOL$1,443
- Tecnis Symfony IOL$1,443
- Tecnis Symfony Toric IOL$1,443
- PanOptix$134
- DURYSTA$125
- EYLEA$125
- VABYSMO$122
- Syfovre$122
- LOTEMAX SM$101
How this compares
$4,617 in reported general payments places this provider in the 80th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 47 | $56,830 |
| LumiganBimatoprost | 43 | $31,364 |
| Restasis MultidoseCyclosporine | 13 | $8,897 |
| IlevroNepafenac | 16 | $6,192 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $5,819 |
| Latanoprost | 366 | $4,833 |
| Prednisolone Acetate | 112 | $3,807 |
| Fluorometholone | 54 | $3,319 |
| Gatifloxacin | 40 | $2,319 |
| Bromfenac Sodium | 16 | $1,998 |
| MoxifloxacinMoxifloxacin Hcl | 40 | $1,204 |
| Brimonidine Tartrate | 15 | $935 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $495 |
| Timolol Maleate | 43 | $435 |
| Dorzolamide Hcl | 14 | $242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $204 | $102,910117 claims |
| NovartisIlevro | $57 | $6,19216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.